Bioventus to Release Second Quarter of Fiscal Year 2021 Financial Results on August 10, 2021
Bioventus (BVS) announced it will release its fiscal Q2 2021 results after market close on August 10, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bioventus (BVS) announced it will release its fiscal Q2 2021 results after market close on August 10, 2021. Management will conduct a conference call at 5:00 PM ET the same day to discuss these results and provide a business update. Interested parties can join the call by dialing the provided numbers. A webcast will also be available on the company’s investor relations website, which will be archived for replay until August 10, 2022. The company focuses on delivering clinically proven products for active healing.
Positive
- No significant positive aspects to report.
Negative
- No financial performance metrics or guidance provided in the PR.
Details
News Market Reaction – BVS
The recorded move for BVS in the trading session of this news was +2.75%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DURHAM, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that second quarter of fiscal year 2021 financial results will be released after the market closes on Tuesday, August 10, 2021.
Management will host a conference call to discuss its financial results and provide a business update, with a question and answer session, at 5:00 p.m. Eastern Time on August 10, 2021. Those who would like to participate may dial 844-945-2085 (442-268-1266 for international callers) and provide access code 1650599. A live webcast of the call and any accompanying materials will also be provided on the investor relations section of the Company's website at https://ir.bioventus.com/.
The webcast will be archived on the Company’s website at https://ir.bioventus.com/ and available for replay until August 10, 2022.
About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for pain treatment & joint preservation, restorative therapies and bone graft substitutes. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com, and follow the Company on LinkedIn and Twitter. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.
Investor Inquiries:
Mike Piccinino, CFA, IRC
Westwicke/ICR
Investor.relations@bioventus.com
Media Contact:
Thomas Hill
919-474-6715
thomas.hill@bioventusglobal.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.